- Home
- DPRO vs ZURA Comparison
DPRO vs ZURA Comparison
Compare DPRO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPRO
- ZURA
- Stock Information
- Founded
- DPRO 1998
- ZURA 2022
- Country
- DPRO Canada
- ZURA United States
- Employees
- DPRO N/A
- ZURA N/A
- Industry
- DPRO Aerospace
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DPRO Industrials
- ZURA Health Care
- Exchange
- DPRO Nasdaq
- ZURA Nasdaq
- Market Cap
- DPRO 81.2M
- ZURA 69.9M
- IPO Year
- DPRO N/A
- ZURA N/A
- Fundamental
- Price
- DPRO $4.90
- ZURA $2.02
- Analyst Decision
- DPRO Strong Buy
- ZURA Buy
- Analyst Count
- DPRO 2
- ZURA 10
- Target Price
- DPRO $6.50
- ZURA $12.67
- AVG Volume (30 Days)
- DPRO 1.7M
- ZURA 384.1K
- Earning Date
- DPRO 08-11-2025
- ZURA 08-14-2025
- Dividend Yield
- DPRO N/A
- ZURA N/A
- EPS Growth
- DPRO N/A
- ZURA N/A
- EPS
- DPRO N/A
- ZURA N/A
- Revenue
- DPRO $5,250,872.00
- ZURA N/A
- Revenue This Year
- DPRO $69.58
- ZURA N/A
- Revenue Next Year
- DPRO $100.68
- ZURA N/A
- P/E Ratio
- DPRO N/A
- ZURA N/A
- Revenue Growth
- DPRO 17.08
- ZURA N/A
- 52 Week Low
- DPRO $1.55
- ZURA $0.97
- 52 Week High
- DPRO $7.31
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- DPRO 58.27
- ZURA 71.64
- Support Level
- DPRO $3.85
- ZURA $1.44
- Resistance Level
- DPRO $4.55
- ZURA $2.09
- Average True Range (ATR)
- DPRO 0.33
- ZURA 0.13
- MACD
- DPRO 0.04
- ZURA 0.04
- Stochastic Oscillator
- DPRO 91.55
- ZURA 87.95
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.